Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

A phase 3 trial of intralesional cemiplimab in patients with early-stage cutaneous SCC, newly underway at GW and multiple other sites, will look at how well the immune checkpoint inhibitor ... from ...

The biotech sector remains one of the most dynamic areas of the market, driven by clinical breakthroughs, regulatory ...

Stay informed with the Sun Pharma Stock Liveblog, your comprehensive resource for real-time updates and in-depth analysis of a leading stock. Get the latest details on Sun Pharma, including: Last ...

Credit: PowerUp/Shutterstock. US-based Actio Biosciences has closed a Series B financing round, raising $66m to advance the genetics-driven small molecule therapeutics pipeline aimed at rare and ...

Purdue Pharma’s $7B opioid settlement could advance after states back it The deal calls for members of the Sackler family who own the company to give up ownership and to contribute up to $7 ...

India's top drugmakers are reportedly sitting on their highest cash reserves in at least five years, up over 120% from FY20 ...

In FY25 alone, the cash pile increased by over Rs 10,200 crore, underscoring a decisive shift in the capital allocation priorities of India’s drugmakers ...

OxyContin maker Purdue Pharma ’s latest plan to settle thousands of lawsuits over the toll of opioids could soon move forward after every U.S. state involved agreed to it.

OxyContin maker Purdue Pharma ’s latest plan to settle thousands of lawsuits over the toll of opioids could soon move forward after every U.S. state involved agreed to it.